ORIC-114 shows promise in preclinical cancer study
SOUTH SAN FRANCISCO - ORIC Pharmaceuticals, Inc., a clinical-stage company focusing on cancer treatment resistance, has presented preclinical data on its drug candidate ORIC-114 at the EORTC-NCI-AACR Symposium. The data highlights the drug's potential as a treatment for non-small cell lung cancer (NSCLC) with certain mutations.
Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2024 Symposium attracts academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.
The company's chief scientific officer, Lori Friedman, Ph.D., stated that the preclinical results demonstrate ORIC-114's superior potency and selectivity compared to other EGFR inhibitors. According to the data, ORIC-114 showed tumor regression in all EGFR mutant models tested, including complete responses in a complex atypical mutant EGFR model.
In comparative analyses, ORIC-114 displayed higher potency across EGFR mutational classes while maintaining selectivity similar to that of other inhibitors in cell-based assays. Additionally, no off-target kinase liabilities were identified, suggesting a favorable safety profile.
ORIC-114 has also shown complete molecular responses in circulating tumor DNA from patients with EGFR exon 20 insertion and PACC mutations in a Phase 1 dose escalation study. These findings support the drug's broad therapeutic window.
The drug is currently being evaluated in a global clinical trial for NSCLC patients with EGFR exon 20, HER2 exon 20, and atypical EGFR mutations, with updated data expected in the first half of 2025.
ORIC-114 is an irreversible inhibitor targeting EGFR exon 20, HER2 exon 20, and atypical EGFR mutations. Its brain penetration and oral bioavailability make it a promising candidate for addressing systemic and CNS antitumor activity needs.
The information in this article is based on a press release statement from ORIC Pharmaceuticals.
